HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Serum type I collagen degradation markers, ICTP and CrossLaps, are factors for poor survival in lung cancer.

Abstract
We investigated the prognostic value of the serum markers of type I collagen synthesis (PINP and PICP) and degradation (ICTP and CrossLaps) in 143 lung cancer patients with a local or locally advanced disease or a metastatic disease. The mean values of ICTP, CrossLaps, PINP and PICP were significantly higher in patients with bone metastases than in those without metastases or with only soft tissue metastases. The patients with ICTP < or = 5.0 micrograms/l or CrossLaps < or = 5000 pmol/l had a better prognosis. The histopathological type, the site of metastases or the stage of the disease had no influence on these results. In multivariate regression analysis, both ICTP and CrossLaps in contrast to PINP or PICP, were prognostic factors for poor survival in lung cancer patients. ICTP, CrossLaps, sedimentation rate, hemoglobin and AFOS reached separately weaker, but statistically significant values as predictors of survival with stage and operation.
AuthorsS Ylisirniö, M L Sassi, J Risteli, T Turpeenniemi-Hujanen, A Jukkola
JournalAnticancer research (Anticancer Res) 1999 Nov-Dec Vol. 19 Issue 6C Pg. 5577-81 ISSN: 0250-7005 [Print] Greece
PMID10697621 (Publication Type: Journal Article)
Chemical References
  • Biomarkers, Tumor
  • Collagen Type I
  • Peptide Fragments
  • Peptides
  • Procollagen
  • collagen type I trimeric cross-linked peptide
  • glutamyl-lysyl-alanyl-histidyl-aspartyl-glycyl-glycyl-arginine
  • procollagen Type I N-terminal peptide
  • procollagen type I carboxy terminal peptide
  • Collagen
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor (blood)
  • Collagen (blood, metabolism)
  • Collagen Type I
  • Female
  • Humans
  • Lung Neoplasms (blood, diagnosis, metabolism, mortality)
  • Male
  • Middle Aged
  • Peptide Fragments (blood)
  • Peptides (blood)
  • Procollagen (blood)
  • Prognosis
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: